SCHEMBL2008347

SCHEMBL2008347

CCOc1ccc(-c2ccc(S(=O)(=O)OCCCCC(N)=O)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 1/20 0.44
PARP10 Q53GL7 1/20 0.44
HDAC3 O15379 6/20 0.44
HDAC4 P56524 6/20 0.44
HDAC1 Q13547 6/20 0.44
HDAC7 Q8WUI4 6/20 0.44
HDAC2 Q92769 6/20 0.44
HDAC10 Q969S8 6/20 0.44
HDAC11 Q96DB2 6/20 0.44
HDAC8 Q9BY41 6/20 0.44
HDAC6 Q9UBN7 6/20 0.44
HDAC9 Q9UKV0 6/20 0.44
HDAC5 Q9UQL6 6/20 0.44
L3MBTL1 Q9Y468 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2009235 0.83 ALDH1A1 (0.47) CA12CA1CA9ALDH1A1CTDSP1
SCHEMBL2004234 0.82 MMP2 (0.50) CA12CA1CA2CA9HDAC3
SCHEMBL2013462 0.82 LMNA (0.42) CA12CA1CA2CA9HDAC3
SCHEMBL2012396 0.81 MEN1 (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL2008430 0.81 MEP1B (0.40) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2009137 0.80 HDAC1 (0.42) CA12CA1CA2CA9HDAC1
SCHEMBL2006904 0.80 MMP3 (0.50) CA12CA1CA2CA9HDAC1
SCHEMBL2009256 0.80 CA1 (0.51) CA12CA1CA2CA7CA9
SCHEMBL9709447 0.79 ALDH1A1 (0.51) CA12CA1CA2CA7CA9
SCHEMBL2005594 0.77 MMP2 (0.51) CA12CA1CA2CA9HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964643-B2 Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2011-06-21 US disclosed
EP-1756046-B1 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS UNIV ABERDEEN (GB) 2009-12-09 EP disclosed
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-05-22 US disclosed
EP-1756046-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS The University Court of The University of Aberdeen (GB) 2007-02-28 EP disclosed
WO-2005118528-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions ARSA, CNKSR1, BCL9L CA12 3293/4885CA1 675/4885CA2 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.